
Meaghan Wall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2255991/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations. Journal of Physical Education and Sports Management, 2020, 6, a004994.	1.2	7
2	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Haematologica, 2020, 106, 87-97.	3.5	43
3	Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. Cell Stem Cell, 2019, 25, 258-272.e9.	11.1	60
4	Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal. Experimental Hematology, 2019, 70, 10-23.	0.4	13
5	What does good FISHing look like in MDS?. Leukemia and Lymphoma, 2019, 60, 571-572.	1.3	0
6	Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nature Medicine, 2019, 25, 119-129.	30.7	147
7	Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood, 2017, 129, 3362-3370.	1.4	150
8	Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14756.	12.8	70
9	The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell Lymphoma. Cell Reports, 2016, 14, 1488-1499.	6.4	36
10	A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia. Haematologica, 2015, 100, e60-e62.	3.5	7
11	The molecular pathogenesis of Bâ€cell nonâ€Hodgkin lymphoma. European Journal of Haematology, 2015, 95, 280-293.	2.2	22
12	Essential Developmental, Genomic Stability, and Tumour Suppressor Functions of the Mouse Orthologue of hSSB1/NABP2. PLoS Genetics, 2013, 9, e1003298.	3.5	28